RSV Seasonal Vaccine Introduction and Growth Strategy

Q2 2023 Total to adjusted profit reconciliation Total results Q2 2022 Operating profit (£m) Q2 2023 Operating profit Key commentary (£m) 1,081 2,141 Intangible amortisation 192 184 Intangible impairment 55 4 Major restructuring 134 46 Transaction-related 685 (189) Divestments, significant (139) (16) legal and other Adjusted results 2.008 2,170 GSK Table may not sum due to rounding. See page 19 of GSK's second quarter 2023 earnings release for a full reconciliation. 1. Contingent consideration liabilities 2. Foreign exchange ViiV CCL¹ movements, primarily related to FX2 Receipt of dividend and distribution income, partly offset by legal charges, including charges for the defence of Zantac 24

View entire presentation